Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants

Datos Bibliográficos

ID14905674
AutoresCharlotte O'Halloran (0000-0003-2335-4883, Public Health England, autor de correspondencia), Brian Rice (0000-0002-5416-8058, London School of Hygiene & Tropical Medicine), Ellen White (MRC Clinical Trials Unit at UCL), Monica Desai (0000-0001-8632-9808, University of Manchester), D Dunn (0000-0003-1836-4446, Medical Research Council), David T Dunn, Sheena McCormack (0000-0002-7829-1325, MRC Clinical Trials Unit at UCL), Ann Sullivan (0000-0001-7532-9562, Chelsea and Westminster Hospital NHS Foundation Trust), Ann K Sullivan, David White (0000-0002-6366-2699, University Hospitals Birmingham NHS Foundation Trust), Alan McOwan (Chelsea and Westminster Hospital NHS Foundation Trust), Mitzy Gafos (0000-0002-7894-1498, London School of Hygiene & Tropical Medicine)
Año2019
Volumen74
Páginas246-254
Fecha de publicación2019-12-01
Peer ReviewedSí
Open AccessSí
TipoARTICLE
RevistaInternational Journal of Drug Policy (JOURNAL)
Identificadores de la revistaISSN: 0955-3959 • E-ISSN: 1873-4758
EditorialElsevier BV (PUBLISHER)
DOI10.1016/j.drugpo.2019.10.007
PMID31739177
OpenAlexW2986786140
IdiomaEN
Citas recibidas15
Referencias citadas45

These analyses suggest PrEP remains a feasible and effective HIV prevention method for GBM engaging in chemsex, a practise which is prevalent in this group and has been associated with increased HIV transmission risk

Anal intercourse · Antiretroviral therapy · Drug · Emtricitabine · Family medicine · Human immunodeficiency virus (HIV · Men who have sex with men · Mephedrone · Pre-exposure prophylaxis · Psychiatry · Syphilis · Viral load · Clinical Psychology · Demography · HIV Research and Treatment · HIV, Drug Use, Sexual Risk · HIV/AIDS Research and Interventions · Medicine